60 DEGREES PHARMACEUTICALS, INC. Financing Cash Flow
60 DEGREES PHARMACEUTICALS, INC. (SXTP) reported Financing Cash Flow of $3.37 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- 60 DEGREES PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $0.00.
- 60 DEGREES PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $3.37M, a 98.58% increase year-over-year.
- 60 DEGREES PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $458.61K, a 47034.02% increase year-over-year.
- 60 DEGREES PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $4.28M, a 16.85% decline year-over-year.
- 60 DEGREES PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $6.44M, a 8.73% decline from fiscal 2024.
- 60 DEGREES PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $7.05M, a 8.94% increase from fiscal 2023.
- 60 DEGREES PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $6.47M, a 429.96% increase from fiscal 2022.
- 60 DEGREES PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $1.22M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $3.37M 10-Q · filed 2026-08-14 | $3.83M derived: sum of 3 quarters · filed 2026-08-14 | $8.11M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $3.37M 10-Q · filed 2026-05-15 | $3.83M derived: sum of 2 quarters · filed 2026-05-15 | $8.11M derived: sum of 3 quarters · filed 2026-05-15 | $8.11M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $458.61K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $4.74M derived: sum of 2 quarters · filed 2026-03-30 | $4.74M derived: sum of 3 quarters · filed 2026-08-14 | $6.44M 10-K · filed 2026-03-30 |
| 2025-09-30 | $4.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $4.28M derived: sum of 2 quarters · filed 2026-08-14 | $5.98M 10-Q · filed 2025-11-13 | $5.98M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $1.70M 10-Q · filed 2026-08-14 | $1.70M derived: sum of 3 quarters · filed 2026-08-14 | $6.85M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $1.70M 10-Q · filed 2026-05-15 | $1.70M derived: sum of 2 quarters · filed 2026-05-15 | $6.85M derived: sum of 3 quarters · filed 2026-05-15 | $6.85M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $973.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $5.15M derived: sum of 2 quarters · filed 2026-03-30 | $5.15M derived: sum of 3 quarters · filed 2026-03-30 | $7.05M 10-K · filed 2026-03-30 |
| 2024-09-30 | $5.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $5.15M derived: sum of 2 quarters · filed 2025-11-13 | $7.05M 10-Q · filed 2025-11-13 | $7.05M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$865.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $1.90M 10-Q · filed 2025-08-13 | $1.90M derived: sum of 3 quarters · filed 2025-08-13 | $7.87M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.90M 10-Q · filed 2025-05-15 | $1.90M derived: sum of 2 quarters · filed 2025-05-15 | $7.87M derived: sum of 3 quarters · filed 2025-05-15 | $8.20M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $5.97M derived: sum of 2 quarters · filed 2025-03-27 | $6.29M derived: sum of 3 quarters · filed 2025-03-27 | $6.47M 10-K · filed 2025-03-27 |
| 2023-09-30 | $5.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $6.29M derived: sum of 2 quarters · filed 2024-11-14 | $6.47M 10-Q · filed 2024-11-14 | $6.41M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $321.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $503.46K 10-Q · filed 2024-08-14 | $434.83K derived: sum of 3 quarters · filed 2024-08-14 | $434.83K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $182.39K 10-Q · filed 2024-05-15 | $113.76K derived: sum of 2 quarters · filed 2024-05-15 | $113.76K derived: sum of 3 quarters · filed 2024-05-15 | |
| 2022-12-31 | -$68.63K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$68.63K derived: sum of 2 quarters · filed 2024-04-01 | $1.22M 10-K · filed 2024-04-01 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-20 | $1.29M 10-Q · filed 2023-11-20 | ||
| 2022-06-30 | $1.29M 10-Q · filed 2023-08-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 |